Ildong Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-03-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ildong.com
qQ-lab Daily-IBS for Irritable Bowel Syndrome
Not Applicable
Completed
- Conditions
- Irritable Bowel Syndrome (IBS)
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: gQ-lab daily
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT03964103
Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers
Phase 1
- Conditions
- Healthy
- Interventions
- Drug: COL-144 50mgDrug: COL-144 100mgDrug: COL-144 400mgDrug: PlaceboDrug: COL-144 200mg
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 64
- Registration Number
- NCT03937648
Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis
Not Applicable
- Conditions
- Dermatitis, Atopic
- Interventions
- Dietary Supplement: RHT-3201
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 102
- Registration Number
- NCT03907228
- Locations
- 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT03889145
A Food Effect Study of Besifovir in Healthy Subjects
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT03885778
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 258
- Registration Number
- NCT03761082
Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy
- Conditions
- HypertensionDyslipidemias
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 600
- Registration Number
- NCT03742544
Belviq Tablet® Post Marketing Surveillance Protocol
- Conditions
- Weight Loss
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2018-11-26
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 3000
- Registration Number
- NCT03741010
A Post-marketing Surveillance to Assess Safety and Efficacy of Twotopsplus.
- Conditions
- Hypertension
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 600
- Registration Number
- NCT03655288
- Locations
- 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe
- Conditions
- Mixed Dyslipidemia
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- IlDong Pharmaceutical Co Ltd
- Target Recruit Count
- 600
- Registration Number
- NCT03648788
© Copyright 2025. All Rights Reserved by MedPath